caprolactone has been researched along with Glial Cell Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baixiang, D; Baiyang, L; Dandan, Z; Hongmei, L; Jun, L; Leran, B; Li, Y; Rutong, Y; Yandong, X; Yufu, Z; Zhen, W | 1 |
| Chang, J; Fang, L; Gao, J; Hu, Y; Li, N; Li, W; Shen, Y; Sun, D; Tan, J | 1 |
2 other study(ies) available for caprolactone and Glial Cell Tumors
| Article | Year |
|---|---|
Reduction-responsive PEtOz-SS-PCL micelle with tailored size to overcome blood-brain barrier and enhance doxorubicin antiglioma effect.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Caproates; Cell Survival; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Liberation; Glioma; Lactones; Male; Mice; Mice, Inbred ICR; Micelles; Oxazoles; Particle Size; Polymers; Tissue Distribution | 2017 |
Topics: Animals; Caproates; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; Doxorubicin; Drug Combinations; Drug Delivery Systems; Female; Glioma; Iodine Radioisotopes; Lactones; Mice; Mice, Inbred BALB C; Nanocapsules; Nanoparticles; Nanostructures | 2020 |